Novo submits high-dose Wegovy for FDA approval using voucher

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

AI Summary: Novo Nordisk has formally submitted its application to the FDA to approve a higher-dose formulation of its flagship obesity drug, Wegovy. Leveraging a recently secured priority voucher, the filing is set to potentially expand treatment options for weight management as the review process begins.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 6 months

Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 5 months

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months

Novo Nordisk slashes prices for Ozempic and Wegovy / 6 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months

FDA approves Rucaparib for advanced prostate cancer / 5 months